SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

CHRS

Coherus Oncology, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS beat is overshadowed by a clear revenue miss and heavy dilution from the Q1 offering. Watch for mid-2026 pipeline data readouts (casdozokitug, tagmokitug) as key catalysts; the $167M cash position provides runway but operating burn remains high at ~$58M/quarter.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.71
T+0 close · May 11, 2026 · via day close
Latest settled
−26.02%
T+60 · $1.27
Vs SPY
−30.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $1.71entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $1.71
  3. T+5 · 6mo ago −12.87%α −12.94% · $1.49
  4. T+20 · 5mo ago −20.47%α −18.74% · $1.36
  5. T+60 · 3mo ago −26.02%α −30.41% · $1.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14.3M estimate by 14.0%. LOQTORZI revenue grew 61% YoY to $11.8M, but total revenue was dragged lower than expected, and the company completed a dilutive $53.6M equity offering during the quarter.

Key Financial Metrics

EPS
−$0.27
est −$0.29 · +6.9%
Revenue
$12.3M
est $14.3M · -13.9% · +62.0% YoY
Rating
miss
Gross Margin
69%

Key Facts

  • GAAP EPS from continuing operations: -$0.27 vs consensus -$0.29 (beat by 6.9%)
  • Revenue: $12.3M vs consensus $14.3M (miss by 14.0%)
  • LOQTORZI net product revenue: $11.8M, up 61% YoY from $7.3M
  • Net loss from continuing operations improved to -$36.9M from -$47.4M YoY
  • Cash, equivalents and marketable securities: $167.0M at quarter-end
  • Completed public offering of 32.89M shares for net proceeds of $53.6M in Q1 2026
  • Operating cash flow: -$57.9M in Q1 2026 vs -$25.8M in Q1 2025
  • Pipeline catalysts: casdozokitug Phase 2 1L HCC data expected mid-2026; tagmokitug multiple readouts in 2026

Financial Impact

Revenue miss of $2.0M (14%) vs consensus; EPS beat of $0.02 (6.9%); $53.6M dilutive equity offering increased share count by ~31%

revenueepsdilutioncash

Risk Factors

  • Revenue miss of 14% vs consensus signals weaker-than-expected LOQTORZI adoption
  • Dilution of ~31% from Q1 equity offering pressures per-share metrics
  • Operating cash burn of -$57.9M in Q1 2026, up from -$25.8M YoY
  • Heavy reliance on pipeline data readouts for valuation inflection

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292299

Track record

15 reports on CHRS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Viewing Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026